Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKIs) are the main class of drugs used to treat chronic myeloid leukemia. Because most CML patients must remain on TKIs indefinitely, it is important to understand and monitor adverse events (AEs). Changes to blood cells, or hematological adverse events, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kronick, Olivia, Chen, Xinyu, Mehra, Nidhi, Varmeziar, Armon, Fisher, Rachel, Kartchner, David, Kota, Vamsi, Mitchell, Cassie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486908/
https://www.ncbi.nlm.nih.gov/pubmed/37686630
http://dx.doi.org/10.3390/cancers15174354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486908/
https://www.ncbi.nlm.nih.gov/pubmed/37686630
http://dx.doi.org/10.3390/cancers15174354

Ejemplares similares